Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (GB:0K1R)
LSE:0K1R
RESEARCH TOOLSreports
Holding GB:0K1R?
Track your performance easily
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -26.23%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.Company Guidance
During Viridian Therapeutics' Q1 2024 earnings call, the company provided several updates on their pipeline and financial outlook. Viridian announced the completion of enrollment for their THRIVE Phase III trial for the 001 IV program, surpassing the target with 113 patients. They anticipate top-line results in September 2024 and plan a BLA submission for the 001 program in the second half of 2025. The company also highlighted progress in their FcRn portfolio, with an IND for 006 expected by the end of 2024 and 008 nonhuman primate data anticipated in the second half of 2024. Viridian ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026.Completion of THRIVE Phase III Enrollment
The THRIVE Phase III trial evaluating 001 in patients with active TED completed enrollment ahead of schedule with 113 patients, exceeding the target of 90 due to strong patient demand.
Strong Financial Position
Viridian ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026.
Positive FDA Meeting for Subcutaneous 003 Program
The company completed a positive Type C meeting with the FDA for the subcutaneous 003 program and is on track to initiate pivotal clinical trials midyear.
Progress in FcRn Portfolio
Viridian is making progress with its FcRn portfolio, aiming to file an IND for 006 by the end of the year, and plans to share 008 nonhuman primate data in the second half of 2024.
---
GB:0K1R Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0K1R Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $26.00 | $24.02 | -7.62% |
| Aug 08, 2024 | $15.26 | $14.98 | -1.83% |
| May 08, 2024 | $15.00 | $14.68 | -2.13% |
| Mar 13, 2024 | $18.29 | $17.71 | -3.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Viridian Therapeutics (GB:0K1R) report earnings?
Viridian Therapeutics (GB:0K1R) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Viridian Therapeutics (GB:0K1R) earnings time?
Viridian Therapeutics (GB:0K1R) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Viridian Therapeutics stock?
The P/E ratio of Viridian Therapeutics is N/A.
What is GB:0K1R EPS forecast?
Currently, no data Available
---